A manufacturer ready to launch in a dozen EU member states quickly discovers that “translate the IFU” isn’t one task. It’s potentially two dozen different language decisions, since each member state can set its own rules under the same regulation. The global medical device market passed roughly $572 billion in 2025 and is projected to exceed $1 trillion by 2034, and Europe alone accounts for more than a quarter of that trade. Entering markets at that scale takes more than good engineering; it takes documentation that satisfies each regulator’s language expectations. That’s where medical device translation becomes a compliance requirement with real consequences for approval timelines, not a line item to handle after the engineering is done.
TL;DR
Medical device translation is a critical part of regulatory compliance, not just language conversion. Manufacturers must meet different FDA and EU MDR labeling requirements, translate key documents accurately, and maintain consistent terminology across all materials. Following regulatory best practices and working with specialized medical device translators helps ensure patient safety, avoid compliance issues, and accelerate global market approvals.
Why This Isn’t Just a Translation Task
Patient safety sits at the center of every labeling requirement. A user who can’t understand a warning or dosage instruction is at risk regardless of how well the device performs. Regulators treat translated documentation as part of the compliance package itself, not a supporting attachment, so an inaccurate or incomplete translation can hold up an entire launch, trigger a corrective action request, or in serious cases contribute to a recall. For manufacturers moving into several countries at once, the quality of their medical device translation services directly affects how fast the rest of the launch happens.
How the FDA Approaches Labeling
For the U.S. market, FDA labeling requirements under 21 CFR Part 801 call for label statements to appear in English. Under 21 CFR 801.15, all labeling must be in English, with one narrow exception: products distributed solely within Puerto Rico or U.S. territories where the predominant language isn’t English. If a foreign-language claim appears anywhere on the label, that same information generally has to appear in English too. English isn’t optional once other languages are present.
Section 801.15 also governs the use of symbols in labeling. When a manufacturer uses a symbol recognized under ISO 15223-1 without adjacent explanatory text, a symbols glossary has to accompany the device, and its location must be stated prominently. Labeling also covers Unique Device Identifier (UDI) content required under 21 CFR Part 830 and Part 801 Subpart B, which must be submitted to the FDA’s Global Unique Device Identification Database (GUDID). Because the FDA reviews all of this as one labeling package, terminology has to stay consistent across every document a device ships with. Mismatched wording between the label and the IFU is exactly the kind of detail that draws scrutiny during review.
How EU MDR Handles Language
The EU takes a more decentralized approach. Under EU MDR translation requirements, Regulation 2017/745 Annex I Section 23 and Annex II require that device information, including labels and IFUs, appear in the official language(s) of the member state where a device is sold, and each of the 27 member states decides individually which language(s) it accepts. Some countries require the national language regardless of who’s using the device; others allow exceptions for products used exclusively by healthcare professionals. Malta and Ireland are the only member states that generally accept English for lay users, since it functions as a native language there.
Clinical documentation carries its own language obligations. Under MDCG 2019-9 guidance, Summary of Safety and Clinical Performance (SSCP) content intended for patients should be translated into all the languages required for lay-user IFUs in the relevant member states, plus English if it isn’t already one of them, since English remains the standard language of scientific publication. A related regulation, EU 2021/2226, also allows electronic IFUs (e-IFUs) for certain professional-use devices, but the underlying language obligation doesn’t change just because the format does. A single EU-wide launch can still call for a distinct set of translated materials for nearly every country involved, along with documentation supporting CE marking and the technical file a Notified Body reviews.
FDA vs. EU MDR: Key Differences
FDA | EU MDR | |
Primary market | United States | 27 EU member states |
Language approach | English required, with a narrow Puerto Rico exception | Set individually by each member state |
Governing framework | 21 CFR Part 801 | Regulation (EU) 2017/745, plus EU 2021/2226 for e-IFUs |
Compliance model | Single national standard | Country-specific compliance across the EU |
Which Documents Actually Need Regulatory-Grade Translation
Any content tied to how a device is understood, used, or evaluated typically falls under these requirements, including:
- Instructions for Use (IFU)
- Labels and packaging
- Technical documentation
- Clinical evaluation reports and SSCP documents
- Risk management files
- User manuals
- Patient information leaflets
- Software user interfaces
- Marketing materials tied to regulated claims
Where Manufacturers Run Into Trouble
A few recurring issues make multi-market medical device labeling translation harder than it looks:
- Technical terminology without a clean equivalent in the target language
- Keeping regulatory language consistent across label, IFU, and technical file
- Frequent product updates that require re-translating already-approved content
- Managing multiple language versions without losing version control
- Formatting and DTP work needed to fit translated text into fixed layouts
- Missing or softened safety warnings, which regulators treat as a direct non-compliance issue, not a stylistic slip
Best Practices for Staying Compliant
Manufacturers that handle this well tend to follow the same core practices:
- Build and maintain approved terminology glossaries for each device line
- Work with linguists experienced specifically in IFU translation and device content, ideally under an ISO 17100 certified workflow
- Use translation memory to keep updates and repeat content consistent
- Run a dedicated linguistic QA pass, including back-translation for high-risk warnings, before anything is finalized
- Validate translated artwork and labels against the approved source
- Maintain clear version control across every language and market
- Monitor MDR language requirements and country-specific exemptions on an ongoing basis, since member states do revise them
Choosing a Translation Partner for Regulated Devices
A partner suited to this work, including medical device localization across markets, should be able to demonstrate:
- Real experience with device manufacturers, not just general medical content
- Working knowledge of both FDA medical device labeling rules and EU MDR expectations
- ISO 17100 and ISO 13485-aligned translation workflows
- Secure handling of confidential technical files
- A documented QA process specific to regulatory content
- The ability to scale across many languages for a coordinated, multilingual medical device labeling launch
Frequently Asked Questions
What are the EU MDR language requirements for medical devices?
MDR 2017/745 requires labels and IFUs in the official language(s) of the member state where a device is sold, with each of the 27 member states deciding which to require. Only Malta and Ireland generally accept English for lay users.
Does the FDA require medical device translations?
FDA labeling generally must be in English under 21 CFR 801.15. If a foreign language also appears, that content must be included in English too, aside from a narrow Puerto Rico exception.
What medical device documents need to be translated?
IFUs, labels, packaging, technical documentation, clinical evaluation reports, SSCP documents, risk management files, user manuals, patient information leaflets, and software interfaces.
What is the difference between FDA and EU MDR labeling requirements?
The FDA centers on English-language compliance under one national framework. EU MDR leaves language decisions to each member state, with SSCP translations following separate MDCG guidance.
Are Instructions for Use (IFUs) required in local languages?
In the EU, generally yes, in the language(s) accepted by the member state of sale, whether printed or as an e-IFU under EU 2021/2226. In the U.S., English is required regardless of other languages present.
How do manufacturers ensure regulatory-compliant translations?
By using experienced medical device linguists, approved terminology glossaries, structured QA with back-translation for high-risk content, and validation against approved source material.
Can machine translation be used for medical device labeling?
Only with caution. Regulatory and safety-critical labeling still needs review and validation by a qualified human linguist before it reaches a Notified Body or the FDA.
Why is professional medical device translation important for regulatory approval?
Inaccurate or incomplete translations can delay approvals, trigger compliance findings or corrective action requests, or create safety risk for end users.
Conclusion
A successful international device launch depends on translation that’s accurate in both language and regulatory context: documentation that satisfies FDA and EU MDR expectations market by market. Manufacturers that build this into their process from the start avoid the delays that come from getting it wrong. For organizations preparing global product rollouts, Columbus Lang offers a full suite of medical device translation services, from life science localization to website adaptation. When you’re ready to move forward, request a quote today.